Etripamil Nasal Spray: A New At-Home Treatment for PSVT
March 2026
Rx etripamil (Cardamyst) will be the first nasal spray for home treatment of paroxysmal supraventricular tachycardia (PSVT).
This arrhythmia leads to over 200,000 ED visits each year due to sudden, intermittent rapid heart rate episodes, often with other symptoms, such as palpitations, shortness of breath, and dizziness.
Etripamil is a fast-acting nondihydropyridine calcium channel blocker that’s structurally similar to verapamil.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote